5M Total Volume = New Hands and New Eyes to FollowThere is still tremendous upward movement in the cards.
Don't neglect the fact that MAPS (main competitor) can't make any moves until it receives FDA approval and by then LaNEO (Pharmala's cheaper but approved analogue) will be on its way into the hands of Austraila.
There will probably be some summer doldrums but there are some significant milestones up and coming to be on the watch for.
Good luck!